Market open
Aclaris Therapeutics/$ACRS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Aclaris Therapeutics
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
Ticker
$ACRS
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
63
ISIN
US00461U1051
Website
ACRS Metrics
BasicAdvanced
$132M
-
-$1.44
-
-
Price and volume
Market cap
$132M
52-week high
$4.07
52-week low
$0.95
Average daily volume
816K
Financial strength
Total debt to equity
1.67
Management effectiveness
Valuation
Price to revenue (TTM)
6.185
Price to book
0.85
Price to tangible book (TTM)
0.85
Growth
Revenue change (TTM)
-42.87%
Earnings per share change (TTM)
32.20%
3-year revenue growth (CAGR)
40.30%
3-year earnings per share growth (CAGR)
2.05%
What the Analysts think about ACRS
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Aclaris Therapeutics stock.
ACRS Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
ACRS Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
ACRS News
AllArticlesVideos
Aclaris Therapeutics to Participate in the HC Wainwright “HCW@Home” Series
GlobeNewsWire·5 days ago
Aclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewsWire·6 days ago
Aclaris Therapeutics to Participate in Two March Healthcare Conferences
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Aclaris Therapeutics stock?
Aclaris Therapeutics (ACRS) has a market cap of $132M as of May 14, 2025.
What is the P/E ratio for Aclaris Therapeutics stock?
The price to earnings (P/E) ratio for Aclaris Therapeutics (ACRS) stock is 0 as of May 14, 2025.
Does Aclaris Therapeutics stock pay dividends?
No, Aclaris Therapeutics (ACRS) stock does not pay dividends to its shareholders as of May 14, 2025.
When is the next Aclaris Therapeutics dividend payment date?
Aclaris Therapeutics (ACRS) stock does not pay dividends to its shareholders.
What is the beta indicator for Aclaris Therapeutics?
Aclaris Therapeutics (ACRS) does not currently have a Beta indicator.